Moreover, some patients may interrupt their treatment once symptoms improve, not realising the long-term necessity of ongoing supplementation to prevent recurrence of deficiency symptoms
No, Contrave is not classified as a controlled substance
A Phase 2 trial (NCT01311518) was designed to test RGN-352 in ~75 heart attack patients, but was placed on FDA clinical hold in 2011 due to manufacturing (GMP) compliance issues at the contract site not safety concerns with the drug itself
Neither compound has a clear superiority in clinical outcomes the choice is typically guided by physician preference, patient convenience, and regulatory context at the time of prescribing
[DOI] [PMC free article] [PubMed] [Google Scholar] 60.Wang E, Ganti T, Vaou E, Hohler A